Targeting super-enhancer-associated oncogenes in osteosarcoma with THZ2, a covalent CDK7 inhibitor.

Conclusions: Super-enhancer-associated genes contribute to the malignant potential of osteosarcoma, and selectively targeting super-enhancer-associated oncogenes with the specific CDK7 inhibitor THZ2 might be a promising therapeutic strategy for patients with osteosarcoma. PMID: 31937612 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31937612?dopt=Abstract

Source: Clinical Cancer Research - January 13, 2020 Category: Cancer & Oncology Authors: Zhang J, Liu W, Zou C, Zhao Z, Lai Y, Shi Z, Xie X, Huang G, Wang Y, Zhang X, Fan Z, Su Q, Yin J, Shen J Tags: Clin Cancer Res Source Type: research